Maroney Megan
Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, Piscataway, NJ; Monmouth Medical Center, Long Branch, NJ. Email:
Am J Manag Care. 2020 Mar;26(3 Suppl):S55-S61. doi: 10.37765/ajmc.2020.43012.
Schizophrenia is a chronic neuropsychiatric disorder that has a significant impact on the functioning and quality of life of individuals affected by the disease. It affects 0.6% to 1.9% of individuals within the United States, and currently there is no cure. Guidelines recommend a combined treatment approach with both pharmacologic agents and psychological interventions for first-episode psychosis, acute exacerbations, and relapse prevention. Presently, multiple agents are available for the treatment of schizophrenia; however, the majority do not address negative symptoms and cognitive dysfunction, with many patients having debilitating residual symptoms, difficulties with adherence, and drug-related adverse effects. To address these concerns, new research evaluating investigational therapies has been undertaken to examine novel treatment strategies. This review summarizes the schizophrenia treatment guidelines, current treatment strategies, and emerging agents for the management of schizophrenia.
精神分裂症是一种慢性神经精神障碍,对受该疾病影响的个体的功能和生活质量有重大影响。在美国,它影响着0.6%至1.9%的人口,目前尚无治愈方法。指南建议采用药物治疗和心理干预相结合的方法来治疗首发精神病、急性加重期以及预防复发。目前,有多种药物可用于治疗精神分裂症;然而,大多数药物无法解决阴性症状和认知功能障碍,许多患者仍有使人衰弱的残留症状、依从性困难以及与药物相关的不良反应。为了解决这些问题,已经开展了评估研究性疗法的新研究,以检验新的治疗策略。本综述总结了精神分裂症的治疗指南、当前的治疗策略以及用于管理精神分裂症的新兴药物。